Figure 7.

Breast cancer case study for drug pharmacological effect evaluation with C2Maps. (a) Distribution of directionality categories for breast cancer; (b) A drug-target subnetwork with directionality information specific for Tamoxifen; (c) Drug effect evaluation for Tamoxifenon breast cancer subtype - luminal A; (d) Drug effect evaluation for Tamoxifenon breast cancer subtype - basal-like; (e) A drug-target subnetworkwith the directionality information specific for Plicamycin; (f) Drug effect evaluation for Plicamycinon breast cancer subtype - luminal A.

Huang et al. BMC Genomics 2012 13(Suppl 6):S17   doi:10.1186/1471-2164-13-S6-S17